Newport Beach, California based Hoag Hospital emerged as one of the first three trial sites across the United States enrolling patients in a post-market study designed to collect real-world clinical outcomes for a new mitral valve replacement option. Now recruiting patients for the MOMENTIS study, Hoag Hospital investigators will follow local patients who received the MITRIS RESILIA valve developed by Edwards Life Sciences, a local Orange County medical device company. Jeffrey M. Carlton, Heart & Vascular Institute leads the study, which tests innovative devices developed by the Orange County-based device manufacturer to ease the orientation of the initial valve placement and bioprosthetic tissue treatment to resist calcification.